RxDoctor Payments DataLook up a doctor →

Devin Sherman, MD

Internal Medicine · Franklin, TNNPI 1659497592

Payments from drug & device makers

$190,962in general payments, 2019–2025

Across 468 payments — averaging $408.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$109K
  • Sanofi$20K
  • Boehringer Ingelheim$19K
  • Olympus Corporation Of The Americas$13K
  • GSK$9K
  • Olympus America Inc.$8K
  • plus $12K from 40 others

What the payments were for

  • Consulting fees$10,2345%
  • Speaking & faculty fees$152,60480%
  • Travel & lodging$4,5922%
  • Food & beverage$10,4865%
  • Education$13,0477%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$190,962 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$260,440
Medicare patients
768
Services billed
2,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter222$215,636
Breztri AerosphereBudesonide/Glycopyr/Formoterol221$159,715
XolairOmalizumab28$112,541
EliquisApixaban182$101,910
Dupixent PenDupilumab26$95,563
Breo ElliptaFluticasone/Vilanterol109$65,540
Stiolto RespimatTiotropium Br/Olodaterol Hcl117$63,945
Dupixent SyringeDupilumab16$61,168
Spiriva RespimatTiotropium Bromide68$46,246
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr82$45,336
SymbicortBudesonide/Formoterol Fumarate56$19,287
MyrbetriqMirabegron43$18,852
XareltoRivaroxaban22$16,750
DuleraMometasone/Formoterol41$15,053
Combivent RespimatIpratropium/Albuterol Sulfate19$14,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$9,007$334,006433 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$109,278$190,547304 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat, Jardiance$19,049$133,768220 claims
PfizerEliquis, Abrysvo$59$106,651197 claims
Johnson & JohnsonXarelto$218$16,75022 claims
MerckDulera$60$15,05341 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$121$7,99618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Franklin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →